American Association for Cancer Research
Browse

FIGURE 2 from Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner

Download (421.51 kB)
figure
posted on 2024-02-19, 14:20 authored by Mariko Takami, Takahiro Aoki, Katsuhiro Nishimura, Hidekazu Tanaka, Atsushi Onodera, Shinichiro Motohashi
<p>6B11 mAb induces degranulation of iNKT cells toward K562 cells. PBMCs isolated from healthy donors were cultured in the presence of α-GalCer and IL2 for 9–10 days, followed by sorting using Vα24-FITC Ab/FITC MicroBeads. Sorted iNKT cells were maintained in the presence of IL2 overnight and then washed. iNKT cells were then maintained in the presence of IL2 until analysis. <b>A,</b> Sorted iNKT cells were maintained overnight and then the culture supernatant was collected. The culture supernatant depleted with anti-mouse Ig beads or the control was added to iNKT cell cultures overnight prior to coculture with K562 cells for the CD107a assay. <b>B,</b> Sorted iNKT cells treated with the 6B11 mAb (10, 50, and 100 ng/ mL) or isotype mAb (mIgG1, 50 ng/mL) were cocultured with K562 cells for CD107a assays. <b>C,</b> Sorted iNKT cells treated with the 6B11 mAb (50 ng/mL) or isotype mAb (50 ng/mL) were cocultured with K562 cells at E/T ratios of 10:1, 5:1, and 2.5:1. An LDH release assay was then performed. <b>D,</b> Sorted iNKT cells treated with the 6B11 mAb (50 ng/ mL) or isotype (mIgG1, 50 ng/mL) were cocultured with K562 cells. Culture supernatants were collected for Cytometric Bead Array to assess IFNγ and TNFα production. <b>E,</b> iNKT cells were treated with the 6B11 mAb and anti-CD3e (UCHT1), anti-CD28, anti-CD2, or isotype control Abs overnight. iNKT cells were then washed and cocultured with K562 cells. Data are representative of two independent experiments. Data represent the mean ± SEM. *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; ***, <i>P</i> < 0.001; ****, <i>P</i> < 0.0001. HD, healthy donor.</p>

Funding

MEXT | Japan Society for the Promotion of Science (JSPS)

Takeda Science Foundation (TSF)

Chiba University Futuristic Medical Fund

History

ARTICLE ABSTRACT

Invariant natural killer T (iNKT) cells play an essential role in antitumor immunity by exerting cytotoxicity and producing massive amounts of cytokines. iNKT cells express invariant T-cell receptors (TCR) to recognize their cognate glycolipid antigens such as α-galactosylceramide (α-GalCer) presented on CD1d. We recently reported that iNKT cells recognize CD1d-negative leukemia cell line K562 in a TCR-dependent manner. However, it remains controversial how iNKT cells use TCRs to recognize and exhibit cytotoxic activity toward CD1d-negative tumors cells without CD1d restriction. Here, we report that iNKT cells exerted cytotoxicity toward K562 cells via a carried over anti-Vα24 TCR mAb from positive selection by magnetic bead sorting. We found that addition of the anti-Vα24Jα18 TCR mAb (6B11 mAb) rendered iNKT cells cytotoxic to K562 cells in an FcγRII (CD32)-dependent manner. Moreover, iNKT cells treated with 6B11 mAb became cytotoxic to other CD32+ cell lines (U937 and Daudi). In addition, iNKT cells treated with 6B11 mAb suppressed K562 cell growth in a murine xenograft model in vivo. These data suggest that anti-iNKT TCR mAb treatment of iNKT cells can be applied as a therapeutic strategy to treat CD32+ cancers such as leukemia, lymphoma, and lung cancer. Our findings unveiled that iNKT cells recognize and kill CD1d-negative target tumors via the anti-iNKT TCR mAb bound to CD32 at the tumor site, thereby bridging iNKT cells and CD1d-negative tumors. These findings shed light on the therapeutic potential of anti-iNKT TCR mAbs in NKT cell–based immunotherapy to treat CD1d-negative CD32+ cancers.

Usage metrics

    Cancer Research Communications

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC